Mohs Surgery Demonstrates 97-99% Cure Rates in Select Early-Stage Melanoma with Real-Time Margin Control
核心洞察
Mohs micrographic surgery achieves a 97% to 99% cure rate for skin cancer, representing the highest among available treatment modalities.
The technique uses real-time margin assessment with immunohistochemical staining (MART-1) to visualize melanoma (搜索) cells during surgery, lowering recurrence risk.
National cancer guidelines do not recommend superficial radiation therapy as first-line treatment; Mohs remains the gold standard for eligible patients.
Mohs micrographic surgery offers cure rates of 97% to 99% for select early-stage melanoma (搜索), combining real-time margin control with tissue-sparing precision that yields excellent cosmetic outcomes, according to experts at Nebraska Medicine (搜索).
The single-day procedure, performed under local anesthesia, involves sequential layer removal with immediate histologic examination while the patient waits. "We repeat the process and look at the margins until the skin cancer is fully removed, and if it is, we perform reconstruction," said Vanessa Voss, MD, a board-certified dermatologist and fellowship-trained Mohs surgeon at Nebraska Medicine (搜索).
MART-1 Staining Enhances Tumor Visualization
A distinguishing feature of the Nebraska Medicine (搜索) program is its use of immunohistochemical staining with MART-1, a marker that renders melanoma (搜索) cells visible during surgery. "We are among the few centers that use an immunohistochemical stain (MART-1) that makes melanoma cells visible during surgery. This helps remove the entire tumor, lowering the risk of cancer recurrence," Dr. Voss explained.
The technique's high cure rate is complemented by its capacity for same-day reconstruction. Reconstructive surgery following Mohs procedures addresses complex anatomical areas including the nose, lips, and eyes. Nebraska Medicine (搜索)'s Mohs surgeons hold extensive training in reconstructive surgery and may collaborate with specialists in facial plastic surgery, oculoplastics, otolaryngology, and general plastic surgery when indicated.
Clinical Indications and Patient Selection
Mohs surgery is indicated for skin cancers in high-risk locations—including the face, head, neck, hands, feet, genitals, and shins—as well as aggressive or high-risk histologic subtypes regardless of body site. Additional high-risk features warranting consideration include rapid growth, lesion size exceeding 2 cm, and immunocompromised status. The technique is also appropriate for select rare tumors such as dermatofibrosarcoma protuberans (DFSP), atypical fibroxanthomas (AFX), and adnexal or spindle cell tumors.
Radiation Therapy: A Limited Role
Addressing patient inquiries about alternative treatments, Dr. Voss emphasized that national cancer guidelines do not recommend superficial radiation therapy (SRT) as first-line treatment for skin cancer. "Mohs remains the gold standard. Radiation is reserved for inoperable tumors; patients unfit for surgery or select adjuvant contexts within a multidisciplinary plan," she stated.
Evidence-Based Referral Tool: The Mohs AUC App
To support primary care physicians in making informed referral decisions, the Mohs Appropriate Use Criteria (AUC) app provides a structured, evidence-based assessment tool. The app generates a score from 0 to 10, with scores of 7 or higher strongly recommending Mohs surgery, scores of 4 to 6 indicating that Mohs may be appropriate depending on additional factors, and scores of 3 or lower suggesting Mohs is generally not recommended.
Multidisciplinary Coordination and Follow-Up Care
Nebraska Medicine (搜索)'s program features weekly multidisciplinary tumor board meetings that bring together specialists in Mohs surgery, radiation oncology, head and neck surgery, plastic surgery, oncology, radiology, and dermatopathology to guide care for rare or complex conditions. As the state's only ACGME-accredited Mohs fellowship program, the center is also dedicated to training the next generation of specialists.
Postoperative management includes acute wound care, healing support, and scar management until healing is complete. For patients residing outside Omaha, the team coordinates follow-up care with local dermatologists for ongoing full-body skin checks, given that a prior skin cancer diagnosis constitutes a key risk factor for future malignancies.